Sec. 147. MedPAC report on shifting coverage of certain Medicare part B drugs to Medicare part D
265 words·~1 min read·
/bill/116/s/2543/rs/section-147·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Medicare Payment Advisory Commission (in this section referred to as the Commission ) shall conduct a study on shifting coverage of certain drugs and biologicals for which payment is currently made under part B of title XVIII of the Social Security Act ( 42 U.S.C. 1395j et seq.) to part D of such title ( 42 U.S.C. 1395w–21 et seq.). Such study shall include an analysis of— differences in program structures and payment methods for drugs and biologicals covered under such parts B and D, including effects of such a shift on program spending, beneficiary cost-sharing liability, and utilization management techniques for such drugs and biologicals; and the feasibility and policy implications of shifting coverage of drugs and biologicals for which payment is currently made under such part B to such part D.
Not later than June 30, 2021, the Commission shall submit to Congress a report containing the results of the study conducted under subsection (a). The report under paragraph
(1)shall include information, and recommendations as the Commission deems appropriate, regarding— formulary design under such part D; the ability of the benefit structure under such part D to control total spending on drugs and biologicals for which payment is currently made under such part B; changes to the bid process under such part D, if any, that may be necessary to integrate coverage of such drugs and biologicals into such part D; and any other changes to the program that Congress should consider in determining whether to shift coverage of such drugs and biologicals from such part B to such part D.
Connectionstraces to 1
Traces to 1 document
1 reference not yet in our index
- 42 USC 1395w–21
Citation graph
cites case law
Sec. 147
MedPAC report on shifting coverage of certain Medicare part B drugs to Medicare part D
Cite42 USC 1395w–21
Cites 2Cited by 0 across 0 sources